EZH2在血液病发生发展中作用的研究进展  

Research Progress of Role of EZH2 in Occurrence and Development of Hematological Diseases

作　　者：徐诺 陈香丽 XU Nuo;CHEN Xiangli(Department of Hematology,the People′s Hospital of Henan University/Henan Provincial People′s Hospital,Zhengzhou 450003,China)

机构地区：[1]河南大学人民医院,河南省人民医院血液科,郑州450003

出　　处：《医学综述》2024年第2期172-176,共5页Medical Recapitulate

基　　金：河南省医学科技攻关计划项目(SBGJ202002010)。

摘　　要：Zeste基因增强子同源物2(EZH2)通过调节染色质结构介导基因沉默,广泛调控细胞周期进程,因此其异常表达具有高度致瘤性,可导致肿瘤的发生及发展。EZH2在骨髓增生异常综合征、急性髓系白血病、非霍奇金淋巴瘤及免疫性血小板减少症等血液病中表达异常,与血液病的发生、发展及预后有关。血液病发病机制复杂,目前有关血液病的基因组学研究发展迅速。EZH2作为血液病常规检测基因,是进一步研究血液病发病机制、预测患者预后、探讨治疗新策略的一个有前景的靶点。Enhancer of Zeste homolog 2(EZH2)mediates gene silencing by regulating chromatin structure and extensively regulates cell cycle progression,so its aberrant expression is highly tumorigenic,which can lead to the occurrence and development of tumors.EZH2 is abnormally expressed in myelodysplastic syndrome,acute myeloid leukemia,non-Hodgkin lymphoma and immune thrombocytopenia,which is related to the occurrence,development and prognosis of hematological diseases.The pathogenesis of hematological diseases is complex,and currently genomics research on hematological diseases is developing rapidly.EZH2,as a gene for routine detection of hematological diseases,is a promising target for further studying the pathogenesis of hematological diseases,predicting the patient prognosiss,and exploring new therapeutic strategies.

关 键 词：血液病 Zeste基因增强子同源物2 致癌作用 抑癌作用 耐药性 

分 类 号：R55[医药卫生—血液循环系统疾病]